Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer?
PD-1
PD-L1
colorectal neoplasms
longitudinal survival analysis
tumor burden
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
received:
25
07
2022
revised:
12
08
2022
accepted:
15
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) have been reported as possibly favorable prognostic factors in colorectal cancer (CRC). However, their longitudinal effect is unknown. A pilot study was performed to investigate whether baseline PD-1/PD-L1 levels are associated with further laboratory changes and/or shorter survival. A total of 506 laboratory measurements from 37 metastatic CRC patients were analyzed. The baseline plasma PD-1 and PD-L1 levels were 27.73 ± 1.20 pg/mL and 16.01 ± 1.09 pg/mL, respectively. Disease progression ( Abnormal levels of laboratory parameters and intensified tumor burden can be expected if elevated baseline plasma PD-1/PD-L1 levels are found.
Sections du résumé
BACKGROUND
BACKGROUND
Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) have been reported as possibly favorable prognostic factors in colorectal cancer (CRC). However, their longitudinal effect is unknown.
METHODS
METHODS
A pilot study was performed to investigate whether baseline PD-1/PD-L1 levels are associated with further laboratory changes and/or shorter survival.
RESULTS
RESULTS
A total of 506 laboratory measurements from 37 metastatic CRC patients were analyzed. The baseline plasma PD-1 and PD-L1 levels were 27.73 ± 1.20 pg/mL and 16.01 ± 1.09 pg/mL, respectively. Disease progression (
CONCLUSIONS
CONCLUSIONS
Abnormal levels of laboratory parameters and intensified tumor burden can be expected if elevated baseline plasma PD-1/PD-L1 levels are found.
Identifiants
pubmed: 36013050
pii: jcm11164815
doi: 10.3390/jcm11164815
pmc: PMC9410536
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research, Development and Innovation Office (Hungary)
ID : NVKP_16-1-2016-0004
Organisme : National Research, Development and Innovation Office (Hungary)
ID : NVKP_16-1-2016-0042
Organisme : Spectrum Radiology for Health Foundation
ID : APC coverage
Organisme : Semmelweis University
ID : APC coverage
Références
Nat Rev Cancer. 2022 Mar;22(3):174-189
pubmed: 35031777
Cancer Res Treat. 2021 Jan;53(1):199-206
pubmed: 33070562
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
Cancer Immunol Immunother. 2020 Dec;69(12):2533-2546
pubmed: 32577816
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Gastroenterology Res. 2018 Aug;11(4):264-273
pubmed: 30116425
Cancers (Basel). 2020 Feb 28;12(3):
pubmed: 32121060
Crit Rev Oncol Hematol. 2022 May;173:103663
pubmed: 35351582
Sci Rep. 2021 Oct 5;11(1):19712
pubmed: 34611279
Cancers (Basel). 2021 May 22;13(11):
pubmed: 34067347
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Clin Exp Pathol. 2019 May 01;12(5):1764-1769
pubmed: 31933995
Cell Commun Signal. 2022 Jan 28;20(1):14
pubmed: 35090497
Platelets. 2016 Jun;27(4):269-75
pubmed: 27136385
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
Gan To Kagaku Ryoho. 2018 Aug;45(8):1159-1163
pubmed: 30158411
JAMA. 2021 Feb 16;325(7):669-685
pubmed: 33591350
PLoS One. 2021 Nov 15;16(11):e0260124
pubmed: 34780566
Mod Pathol. 2016 Sep;29(9):1104-12
pubmed: 27198569
Int Immunopharmacol. 2021 May;94:107467
pubmed: 33611059
Oncotarget. 2017 Mar 14;8(11):18021-18030
pubmed: 28152514
World J Surg Oncol. 2022 Mar 24;20(1):93
pubmed: 35331250
World J Gastroenterol. 2019 Aug 7;25(29):3920-3928
pubmed: 31413527
ESMO Open. 2020 Nov;5(6):e000863
pubmed: 33184096
Front Immunol. 2022 Mar 21;13:827921
pubmed: 35386715
Eur Respir J. 2019 Jan 31;53(2):
pubmed: 30487198
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
Sci Rep. 2018 Apr 26;8(1):6564
pubmed: 29700384
Am J Reprod Immunol. 2020 Jan;83(1):e13193
pubmed: 31585483
Cancer Immunol Immunother. 2022 Mar;71(3):661-674
pubmed: 34322779
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Cancers (Basel). 2021 Nov 21;13(22):
pubmed: 34830993
Oncol Lett. 2017 Nov;14(5):6071-6078
pubmed: 29113248
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2021 Jul 16;13(14):
pubmed: 34298779
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33239417
Transl Cancer Res. 2020 Apr;9(4):2434-2448
pubmed: 35117603
Science. 2020 Apr 10;368(6487):
pubmed: 32273439
Cancer Res Treat. 2019 Apr;51(2):832-840
pubmed: 30309223
Oncoimmunology. 2020 Nov 25;9(1):1846901
pubmed: 33299657
Diagnostics (Basel). 2022 Jan 13;12(1):
pubmed: 35054356
Genes Dis. 2021 Sep 20;9(5):1181-1193
pubmed: 35873032
J Cell Physiol. 2020 Jul;235(7-8):5461-5475
pubmed: 31960962
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Sci Rep. 2020 Jun 3;10(1):9077
pubmed: 32493964
PLoS One. 2019 Feb 26;14(2):e0212978
pubmed: 30807610
Dokl Biochem Biophys. 2021 Mar;497(1):66-70
pubmed: 33895919
Sci Rep. 2020 Feb 25;10(1):3392
pubmed: 32099055
Biomedicines. 2021 Dec 16;9(12):
pubmed: 34944745
Int J Inflam. 2020 Sep 8;2020:9476326
pubmed: 32963755
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Thorac Cancer. 2020 Nov;11(11):3193-3204
pubmed: 32941706
Int Immunol. 1995 Jun;7(6):947-55
pubmed: 7577803
Am J Cancer Res. 2019 Feb 01;9(2):219-227
pubmed: 30906624
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35131863
BMC Cancer. 2019 Apr 16;19(1):360
pubmed: 30992011
J Diabetes Complications. 2017 Sep;31(9):1376-1383
pubmed: 28711195
Clin Lab. 2019 Sep 1;65(9):
pubmed: 31532095
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
J Hematol Oncol. 2022 Jul 16;15(1):95
pubmed: 35842707
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Cancers (Basel). 2021 Dec 16;13(24):
pubmed: 34944931
Cancer Immunol Immunother. 2021 Oct;70(10):2893-2909
pubmed: 33688997
Nat Commun. 2021 Dec 1;12(1):7005
pubmed: 34853305
Cancers (Basel). 2021 Feb 07;13(4):
pubmed: 33562338
Front Med (Lausanne). 2021 Oct 15;8:727412
pubmed: 34722568
Lung Cancer. 2019 Jun;132:36-38
pubmed: 31097091
Stat Methods Med Res. 2016 Jun;25(3):1057-73
pubmed: 26092476
Oncotarget. 2016 Nov 22;7(47):76604-76612
pubmed: 27780932
Integr Cancer Ther. 2018 Dec;17(4):1297-1303
pubmed: 30193538
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
World J Surg Oncol. 2018 Sep 25;16(1):192
pubmed: 30253767